[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xenon Pharmaceuticals Inc (XENE)

Xenon Pharmaceuticals Inc (XENE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,413,296
  • Shares Outstanding, K 96,666
  • Annual Sales, $ 7,500 K
  • Annual Income, $ -345,910 K
  • EBIT $ -413 M
  • EBITDA $ -410 M
  • 60-Month Beta 0.65
  • Price/Sales 720.23
  • Price/Cash Flow N/A
  • Price/Book 4.04

Options Overview Details

View History
  • Implied Volatility 46.84% (-1.42%)
  • Historical Volatility 27.60%
  • IV Percentile 15%
  • IV Rank 8.10%
  • IV High 176.33% on 02/20/26
  • IV Low 35.42% on 05/21/25
  • Expected Move (DTE 34) 5.31 (9.77%)
  • Put/Call Vol Ratio 4.84
  • Today's Volume 1,262
  • Volume Avg (30-Day) 526
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 18,067
  • Open Int (30-Day) 18,997
  • Expected Range 49.08 to 59.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.16
  • Number of Estimates 9
  • High Estimate $-0.99
  • Low Estimate $-1.46
  • Prior Year $-1.07
  • Growth Rate Est. (year over year) -8.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.30 +2.05%
on 04/28/26
59.87 -9.15%
on 04/17/26
-4.49 (-7.63%)
since 04/15/26
3-Month
40.86 +33.11%
on 02/17/26
63.95 -14.95%
on 03/10/26
+12.91 (+31.12%)
since 02/13/26
52-Week
28.19 +92.94%
on 05/30/25
63.95 -14.95%
on 03/10/26
+24.82 (+83.94%)
since 05/15/25

Most Recent Stories

More News
Xenon Pharmaceuticals Q1 Earnings Call Highlights

Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure...

XENE : 54.39 (-2.88%)
Xenon Pharmaceuticals: Q1 Earnings Snapshot

Xenon Pharmaceuticals: Q1 Earnings Snapshot

XENE : 54.39 (-2.88%)
Xenon Reports Q1 2026 Financial Results and Provides Business Update

Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026 Five additional Phase 3 studies of azetukalner continue to enroll in...

XENE : 54.39 (-2.88%)
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, MA, May 01, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 54.39 (-2.88%)
Xenon to Report Q1 2026 Financial Results on May 7, 2026

VANCOUVER, British Columbia and BOSTON, MA, April 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...

XENE : 54.39 (-2.88%)
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time points X-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in monthly...

XENE : 54.39 (-2.88%)
Xenon to Present at Upcoming Investor Conferences

VANCOUVER, British Columbia and BOSTON, MA, April 15, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...

XENE : 54.39 (-2.88%)
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting

Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures Poster presentations also include long-term...

XENE : 54.39 (-2.88%)
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

VANCOUVER, British Columbia and BOSTON, MA, March 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...

XENE : 54.39 (-2.88%)
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

VANCOUVER, British Columbia and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 54.39 (-2.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan...

See More

Key Turning Points

3rd Resistance Point 56.73
2nd Resistance Point 56.23
1st Resistance Point 55.31
Last Price 54.39
1st Support Level 53.89
2nd Support Level 53.39
3rd Support Level 52.47

See More

52-Week High 63.95
Last Price 54.39
Fibonacci 61.8% 50.29
Fibonacci 50% 46.07
Fibonacci 38.2% 41.85
52-Week Low 28.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.